Alessandro Maria V.
- Country
- Italy
- Department
- Hematology
Research Overview
- Evaluation of INCA033989 Efficacy and Safety in Patients with Myelofibrosis or Essential Thrombocythemia within Myeloproliferative Neoplasms
- A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms
- Phase 1 Study of PRT12396 in Patients with High‑Risk Polycythemia Vera and Post‑ET or Post‑PV Myelofibrosis and Intermediate/High‑Risk Primary Myelofibrosis
Data & Insights
Has run more than one trial at 163 of 324 partner sites.
Specializations
Myelofibrosis Research
This investigator focuses extensively on myelofibrosis treatment approaches, including studies of novel therapeutic combinations and targeted interventions. Their work encompasses primary myelofibrosis and secondary forms developing from other conditions.
- Novel therapeutic combinations with ruxolitinib
- Treatment strategies for JAK inhibitor-resistant cases
- Management of transfusion-dependent myelofibrosis
Hematologic Malignancies
The investigator conducts research in various blood-related cancers and disorders, with particular attention to acute myeloid leukemia and related conditions.
- FLT3-mutated acute myeloid leukemia
- Chronic myeloproliferative neoplasms
- Essential thrombocythemia management
Rare Blood Disorders
Their research extends to rare hematologic conditions, including paroxysmal nocturnal hemoglobinuria and polycythemia vera.
- Complement inhibitor therapies
- Novel treatment approaches for polycythemia vera
- Long-term safety studies of innovative therapies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.